Table 1.
Characteristics∗ median (IQR) or N (column %) | Overall (n = 1645) | Deceased (n = 115) | Not deceased (n = 1530) | P† |
Baseline age, y | 38 (31–45) | 44 (38–52) | 37 (31–45) | <.001 |
Sex | .89 | |||
Male | 1289 (78.4) | 89 (77.4) | 1,200 (78.4) | |
Female | 356 (21.6) | 26 (22.6) | 330 (21.6) | |
Race/ethnicity | .008 | |||
Non-Hispanic/Latino white | 743 (45.2) | 38 (33.0) | 705 (46.1) | |
Non-Hispanic/Latino black | 606 (36.8) | 55 (47.8) | 551 (36.0) | |
Hispanic/Latino ethnicity | 224 (13.6) | 20 (17.4) | 204 (13.3) | |
Other race/ethnicity | 72 (4.4) | 2 (1.7) | 70 (4.6) | |
HIV risk activity | <.001 | |||
MSM | 929 (56.5) | 34 (29.6) | 895 (58.5) | |
PWID | 90 (5.5) | 24 (20.9) | 66 (4.3) | |
Heterosexual | 525 (31.9) | 49 (42.6) | 476 (31.1) | |
Unknown/other risk | 101 (6.1) | 8 (7.0) | 93 (6.1) | |
Payer | <.001 | |||
Private | 882 (53.6) | 45 (39.1) | 837 (54.7) | |
Public | 506 (30.8) | 57 (49.6) | 449 (29.4) | |
None/unknown/other | 257 (15.6) | 13 (11.3) | 244 (15.9) | |
CD4+ cell count (cells/mm3), pre-cART | 293 (140–460) | 144 (40–274) | 308 (154–473) | <.001 |
Observation duration, median y | 5.2 (2.5–9.1) | 4.3 (2.0–8.6) | 5.2 (2.5–9.2) | .07 |
cART = combination antiretroviral therapy, IQR = interquartile range, MSM = men who have sex with men, PWID = persons who inject drugs.
Characteristics are summarized at baseline (defined as the date 6 months after cART initiation), unless otherwise indicated.
Wilcoxon rank-sum tests for continuous variables, Yates-corrected chi-square test for categorical variables comparing characteristics of deceased and nondeceased participants.